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A B S T R A C T
We developed a mouse model for central post-stroke pain (CPSP), a centrally-originated neuropathic pain
(NeuP). In this mode, mice were first injected with Rose Bengal, followed by photo-irradiation of left middle
cerebral artery (MCA) to generate thrombosis. Although the MCA thrombosis was soon dissolved, the reduced
blood flow remained for more than 24 h due to subsequent occlusion of microvessels. This photochemically
induced thrombosis (PIT) model showed a hypersensitivity to the electrical stimulation of both sides of paw, but
did not show any abnormal pain in popular thermal or mechanical nociception tests. When tissue-type plas-
minogen activator (tPA) was injected 6 h after the PIT stress, tPA-dependent hypersensitivity to the electrical
paw stimulation and stable thermal and mechanical hyperalgesia on both sides for more than 17 or 18 days after
the PIT treatment. These hyperalgesic effects were abolished in lysophosphatidic acid receptor 1 (LPA1)- and
lysophosphatidic acid receptor 3 (LPA3)-deficient mice. When Ki-16425, an LPA1 and LPA3 antagonist was
treated twice daily for 6 days consecutively, the thermal and mechanical hyperalgesia at day 17 and 18 were
significantly reversed. The liquid chromatography–mass spectrometry (LC–MS/MS) analysis revealed that there
is a significant increase in several species of LPA molecules in somatosensory S-I and medial dorsal thalamus
(MD), but not in striatum or ventroposterior thalamus. All these results suggest that LPA1 and LPA3 signaling
play key roles in the development and maintenance of CPSP.
1. Introduction
Stroke is one of common medical emergencies leading to irrever-
sible neurological damage with severe complications including the
dysfunction of motor skills, cognition, sensory perception and even
death (De Vloo et al., 2017; Jensen and Finnerup, 2013). There are
limited strategies to restore the blood flow to treat acute ischemia
stroke. Tissue plasminogen activator (tPA) has been used for acute
treatment for more than 20 years (Ahmed et al., 2010; Wardlaw et al.,
2014). However, the short time frame for safe intervention has a lim-
itation of clinical use, since it is still estimated that reperfusion strate-
gies could treat less than 10% of all acute stroke patients. One of the
reasons for such a short time window is that intervention beyond this
time window actually increases risk and leads to worsened outcome
(Lees et al., 2010). If these reperfusion therapies are applied too late,
there is an increased risk of cerebral hemorrhage, which can sometimes
prove fatal (The NINDS t-PA Stroke Study Group, 1997). In addition to
“reperfusion injury” due to cerebral hemorrhage complicating ischemic
stroke, the neurotoxicity of tPA has been frequently reported (Wang
et al., 1998). Central post-stroke pain (CPSP) or stroke-induced head-
ache is one of representative cerebral hemorrhage-related toxic events
(Jensen and Finnerup, 2013; Kumral et al., 1995; Tversky et al., 2016).
As the post-stroke pain also has a nature of association with de-
pression and cognitive dysfunction, it is not appropriately recognized
and treated. (Harrison and Field, 2015). The most common types of
post-stroke pain are CPSP, pain due to painful spasms or spasticity,
hemiplegic shoulder pain, complex regional pain syndrome and post-
stroke headache. The CPSP has been characterized as a long-lasting
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constant or intermittent pain syndrome, which is closely related to the
stroke/cerebral ischemia-induced cerebrovascular lesion in the tha-
lamus and other pain-related brain regions (Jensen and Finnerup,
2013).
To pursue the mechanism-based medicine, we have attempted to see
involvements of lysophosphatidic acid receptor 1 (LPA1) in various
chronic pain models, such as partial sciatic nerve injury-induced (Inoue
et al., 2004), paclitaxel-induced (Uchida et al., 2014) and experimental
fibromyalgia-like pain models (Ueda and Neyama, 2017), since we have
firstly demonstrated LPA1-deficient (LPA1-KO) mice abolish abnormal
pain in the partial sciatic nerve ligation (pSNL) model (Inoue et al.,
2004). In a series of our studies, we have also demonstrated that LPA1
signaling plays key roles in the molecular mechanisms underlying de-
velopment of neuropathic pain. For example, the genetic deficiency of
LPA1 in mice lost the pSNL-induced up-regulation of Cavα2δ1 and
ephrin B1 transcription in dorsal root ganglion, which are supposed to
play mechanisms underlying hyperalgesia due to increased spinal pain
transmission, and also lost the pSNL-induced demyelination of dorsal
root fibers, which may be related to a cross-talk between noxious and
innocuous fibers (Ueda, 2017, 2006, 2008; Ueda et al., 2013). In ad-
dition, we have further demonstrated that intense pain signals cause
LPA production in the dorsal horn of spinal cord, which in turn am-
plifies the LPA production through LPA1 and LPA3 signaling via mi-
croglia activation and interleukin 1β production (Ueda, 2017). In the
present study, we attempted to develop a novel type of central neuro-
pathic CPSP model, using photochemically induced thrombosis (PIT)
and tissue plasminogen activator. In addition, we also attempted to see
involvements of LPA1 and LPA3 in such a new model.
2. Materials and methods
2.1. Animals
Total 157 of Male C57BL/6J mice purchased from TEXAM
(Nagasaki, Japan), LPA1- and LPA3-KO mice generously obtained from J
Chun (Stanford Burnham Prebys medical Discovery Institute, La Jolla,
CA) weighing 20–25 g were used for all the experiments. All mice were
kept in a room with a temperature of 21 ± 2 °C with ad libitum access
to a standard laboratory diet and tap water in standard animal cages in
12 h light/dark cycle (lights on at 8:00 a.m.). All procedures used in this
study were approved by Nagasaki University Animal Care and Use
Committee (Animal Experiments Approval Number: 1604221299-5)
and complied with the recommendations of the International
Association for the Study of Pain (Zimmermann, 1983) and ARRIVE
guidelines.
2.2. Photochemically induced thrombosis in left middle cerebral artery
PIT treatment was produced following the protocol as described
previously (Halder et al., 2013a). Briefly, mice were anesthetized with
2% isoflurane (flow rate; 0.5 L/min, Mylan, Tokyo, Japan), maintaining
the rectal temperature at 37.0 ± 0.5 °C using a heating pad. The
temporal muscle was dissected, the skull was exposed, and 2 mm
opening was made over the middle cerebral artery (MCA). Rose Bengal
(RB, tetrachlorotetraiodofluorescein) was purchased from Wako
(Osaka, Japan), dissolved in saline and administered intravenously (i.v.
injection, 30 mg/kg) in mice. To cause thrombosis, photo-illumination
(green light, wavelength: 540 nm, 5000 lx, L-4887, Hamamatsu Pho-
tonics, Hamamatsu, Japan) was applied to the MCA for 10 min, after
which the temporal muscle and skin were replaced. RB is known to
produce reactive oxygen species, which mimic the endogenous en-
dothelial injury process leading to thrombosis (Westrick et al., 2007).
RB is also known to be particularly effective for in vivo studies because
of its high photochemical efficiency and low systemic toxicity (Westrick
et al., 2007). For the preparation of sham-control, mice were treated
with skull-exposure and RB injection, but not given with photo-
illumination.
After the PIT treatment, the cerebral blood flow was monitored by
inserting a probe (diameter 0.5 mm, ALF2100, Advance Co., Tokyo,
Japan) of Doppler flowmeter (ALF21, Advance Co., Tokyo, Japan) into
the left striatum through a guide cannula.
2.3. Tissue-type plasminogen activator (tPA) administration
tPA was purchased as Activacin® for Injection 6 million from Kyowa
Hakko Kirin Co., Ltd. (Tokyo, Japan), dissolved in sterilized PBS
(137 mM NaCl, 2.68 mM KCl, 1.47 mM KH2PO4, 8.1 mM NaHPO4, ad-
justed pH 7.4) and used for i.v. injection at 10 mg/kg via lateral tail
vein at 4.5 or 6 h after PIT-treatment.
2.4. Triphenyltetrazolium chloride staining
For 2,3,5-triphenyltetrazolium chloride (TTC, Sigma-Aldrich, St
Louis, MO) staining, brain was quickly removed, sectioned coronally
with 1 mm thickness and washed with PBS. Brain slices were incubated
with 2% TTC dissolved in 0.9% NaCl in the dark place for 15–20 min at
room temperature (25 °C). Brain slices were incubated with 4% paraf-
ormaldehyde (PFA) overnight at 4 °C. Images of TTC-stained brain
slices were obtained by scanner (EPSON GT-9700F) and infarct volume
was measured by Image J (NIH, Bethesda, MD).
2.5. Histological assessment
Hematoxylin and Eosin (HE) staining was conducted following a
previously described protocol (Ueda et al., 2016). Briefly, brain sections
were washed with PBS, immersed in Mayer’s Hematoxylin solution
(WAKO, Osaka, Japan) for 5 min at 25 °C and then washed with tap
water for 20 min. After a brief treatment with 95% ethanol, sections
were immersed in eosin–alcohol solution (WAKO) for 4 min at 25 °C.
Sections were dehydrated through a series of ethanol solutions, xylene,
and over-slipped with Permount (Fisher Scientific, Waltham, MA, USA).
The analysis of the HE-stained brain sections was performed using a BZ-
8000 microscope with BZ Image Measurement Software (KEYENCE,
Osaka, Japan). The brightness and contrast of all images were adjusted
in Adobe Photoshop (Adobe Systems Inc., San Jose, CA) to the same
conditions.
2.6. Nociception tests
Nociception tests were performed at day 3 through day 19 after the
PIT treatment. Electrical stimulation-induced paw withdrawal (EPW)
test was performed as described previously (Matsumoto et al., 2008;
Ueda, 2008). Briefly, electrodes of Neurometer Current Perception
Threshold/C (CPT/C, Neurotron Inc., Baltimore, MD) were fastened to
the planter and the insteps of hind paw. Transcutaneous nerve stimuli
with each of the three sine-wave pulses (5, 250, and 2000 Hz) were
applied. The minimum intensity (μA) at which each mouse withdrew its
paw was defined as the current threshold. Thermal paw withdrawal test
was performed as described previously (Hargreaves et al., 1988; Uchida
et al., 2010). Unanesthetized mice were placed in Plexiglas cages on top
of a glass sheet and allowed an adaptation period of 1 h. A thermal
stimulator (IITC Inc., Woodland Hills, CA) was positioned under the
glass sheet, and the focus of the projection bulb was aimed precisely at
the middle of the plantar surface of mice. The paw withdrawal latency
(PWL) at which mouse withdrew its paw was defined as the thermal
nociceptive threshold. A cutoff time was set at 20 s to avoid tissue da-
mage. Mechanical paw withdrawal test was performed as described
previously (Uchida et al., 2010). Mice were placed atop a mesh grid
floor in Plexiglas enclosure and allowed to acclimatize for 1 h. A me-
chanical pain stimulus was applied to the middle of the plantar surface
of hind paw by using Electronic digital von Frey Anesthesiometer and
Rigid Tip (Model 2390, 90 g probe, 0.8 mm in outer diameter: IITC Inc.,
H. Ueda, et al. Neurobiology of Pain 5 (2019) 100020
2
Woodland Hills, CA, USA). The pressure required to induce a paw flexor
response was defined as the pain threshold. A cut-off pressure of 20 g
was set to avoid tissue damage. In all behavioral assessments, in-
vestigators blinded to the drug treatment carried out all behavioral
experiments.
2.7. Drug treatments
Ki-16425 was generously provided by Kirin Brewery Co. (Takasaki,
Japan), and was dissolved in 10% dimethyl sulfoxide (DMSO) just be-
fore administration. Before administration, Ki-16425 was diluted in
physiological saline. To evaluate the chronic effect, Ki-16425 was in-
jected 30 mg/kg, i.p. twice a day for 6 consecutive days at started
11 days after PIT treatment. Nociceptive behavioral tests were
performed 24 h after the last administration.
2.8. LC–MS/MS analysis of LPA species in brain loci
The brain loci used for LPA-measurements using LC–MS/MS were
dissected, according to a mouse brain atlas (Parsons and Franklin,
2001). Cortex (S1 and S2), ventral postero-lateral/medial thalamus
(VP: VPL and VPM), medial dorsal nucleus of thalamus (MD) were
dissected from the slice (1.0 mm) at −0.94/−1.94 mm anterior from
the Bregma, while striatum from the slice at 1.18/0.14 mm anterior
from the Bregma, respectively. For the dissection of brain loci, Micro-
puncher 125S and 200S (inner diameter 1.25 and 2.0 mm, respectively)
from Frontier Lab. Ltd., (Fukushima, Japan). The extraction of LPA
from brain loci and the measurement by use of LC–MS/MS were
Fig. 1. Effects of tPA given at different time points on the PIT-induced cerebral infarction. (A) Time course of cerebral blood flow following RB-treatments. The blood
flow was measured before and 5 min after the photo-illumination to the MCA for 10 min in RB (15 or 30 mg/kg, i.v.)-treated mice. Data show the means ± S.E.M.
*p < 0.05, **p < 0.01, 30 mg/kg vs. Vehicle (saline), two-way ANOVA followed by Tukey’s multiple comparisons test. (Interaction, F10,45 = 5.097, P < 0.0001;
Time, F5,45 = 12, P < 0.0001; Drug, F2,45 = 196.2, P < 0.0001). #p < 0.05, ##p < 0.01, 15 mg/kg vs. vehicle, two-way ANOVA followed by Tukey’s multiple
comparisons test. (Interaction, F10,45 = 5.097, P < 0.0001; Time, F5,45 = 12, P < 0.0001; Drug, F2,45 = 196.2, P < 0.0001). (B) Representative pictures of cer-
ebral infarction at sequential brain sections 24 h after the PIT (RB 30 mg/kg i.v.)-treatment. For the preparation of sham-control, mice were treated with skull-
exposure and RB injection, but not given with photo-illumination. (C) Typical pictures showing hemorrhagic blood clots. Results represent the HE-staining of sensory
cortex S-I, striatum and VP thalamus on contralateral and ipsilateral sides. (D) Representative pictures of cerebral infarction with hemorrhagic clots in the brain
section following tPA-treatments at differential time points after the PIT. (E) Quantitation of cerebral infarction volume of brain section following tPA-treatment at
different time points after the PIT. Results represent the infarct volume in the brain section at the level shown in D. Data show the means ± S.E.M. *p < 0.05,
**p < 0.01, one-way ANOVA followed by Tukey’s multiple comparisons test. (F5,18 = 53.77, P < 0.0001). The number of parenthesis indicates the number of mice
used.
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performed, according to the method (Inoue et al., 2011) with minor
modifications. Brain loci dissected at 3 h after the tPA treatment, which
had been given 6 h after the PIT, were sonicated in MeOH with the total
volume of 200 µL. After centrifugation, 50 µL of the supernatant was
diluted 4-fold in MeOH supplemented with an internal standard
(2.5 pmol of LPA 17:0). The supernatant after centrifugation was fil-
trated with Duo-filter (0.2 μm, pore size, 4 mm inner diameter) from
YMC (Kyoto, Japan) and 40 µL of each methanol-extracted sample was
injected to LC–MS/MS system, which was performed using a TSQ
Quantum Ultra triple quadrupole MS (Thermo Fisher Scientific, MA,
USA) equipped with a heated-electrospray ionization-II (HESI-II)
source, with a NANOSPACE SI-II HPLC (Shiseido, Tokyo, Japan). For
the separation of LPA, a Capcell Pak ACR C18 reversed phase column
(1.5 × 250 mm; Shiseido) was used with a gradient of 2 solvents, sol-
vent A (5 mM ammonium formate in water, pH 4.0) and solvent B
(5 mM ammonium formate in 95% [v/v] acetonitrile, pH 4.0), at a flow
rate of 150 µL/min. The initial condition was at 40% solvent A and 60%
solvent B (60% solvent B), followed by a linear gradient to 5% solvent A
and 95% solvent B (95% solvent B) from the time point of 1.2 min to
15 min. The mobile phase (95% solvent B) was continued for another
6 min. After the return of mobile phase to the initial condition (60%
solvent B), column washing process (injection of 40 μL of 2-propanol,
rapid increase from 60% solvent B to 95% solvent B, taking 1.8 min,
constant phase with 95% solvent B for 6 min, and return to 60% solvent
B) was performed. The conditions used for MS/MS analysis were as
follows; the negative HESI-II spray voltage (2500 V), heated capillary
temperature (350 °C), sheath gas pressure (65 psi), auxiliary gas setting
(20 psi), and heated vaporizer temperature (350 °C). Nitrogen was used
for both sheath and auxiliary gases, and collision gas (argon) was set at
1.5 mTorr. All the data were acquired using Xcalibur 2.2 operating
software (Thermo-Fisher Scientific). Various species of LPA were ana-
lyzed by multiple reaction monitoring (MRM) in negative ion mode. Q1
was set for the deprotonated molecular ion for all LPA species (m/z
409.46 for LPA 16:0, m/z 423.49 for LPA 17:0, m/z 437.49 for LPA
18:0, m/z 435.47 for LPA 18:1, and 4m/z 57.46 for LPA 20:4). Q3
(product ion) was set at m/z 153.11 for all species. Peak areas of each
species of 18:1-, 16:0-, 18:0- and 20:4-LPA were normalized to the in-
ternal standard 17:0-LPA, using the same software as described above.
The relative amount of each LPA-species from the preparations treated
with sham, PIT or PIT + tPA on both ipsi- and contralateral side was
calculated as the ratio to the amount of sham-treated and contralateral
side.
2.9. Statistical analysis
All data were presented as means ± S.E.M. Data were analyzed
Fig. 2. Limited features of hyperalgesia induced by PIT-stroke. (A) Experimental time schedule. (B–D) PIT-induced changes in the threshold (μA) of 2000 Hz (B), 250
(C) and 5 Hz (D) electrical stimulation to cause paw withdrawal behaviors at different time points. Significant hyperalgesia on both left and right sides was observed
in the EPW test using 2000 and 250 Hz, but not 5 Hz electrical stimulation. (E, F) The paw withdrawal latency (PWL) in the thermal nociception test (E) and paw
withdrawal threshold in the mechanical nociception test (F) at different time points after the PIT-treatment. No significant hyperalgesia was observed in both tests.
Number in the parenthesis indicates the number of mice per group. (B–F) *p < 0.05, **p < 0.01, two-way ANOVA followed by Bonferroni’s comparisons test. (B:
Interaction, F5,60 = 1.19, P = 0.3250, Time, F5,60 = 0.06697, P = 0.9968, Treatment, F5,60 = 115.9, P < 0.0001; (C) Interaction, F5,60 = 0.4461, P = 0.8144, Time,
F5,60 = 0.6464, P = 0.6653, Treatment, F1,60 = 103.6, P < 0.0001).
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with the GraphPad prism 7.0. (Graphpad Software. San Diego, CA). The
normality of data was first performed and unpaired t-test, F test, Mann-
Whitney test, one-way ANOVA with the Tukey's multiple comparisons
test, two-way ANOVA followed by Tukey’s multiple comparisons test or
Bonferroni’s multiple comparisons test were used for statistical com-
parison. Significance was set at p < 0.05.
3. Results
3.1. Mouse PIT model showing narrow therapeutic window of tPA
The blood flow of MCA detectable after the opening of a small part
of left skull became invisible by the 10 min irradiation with 5000 lx
lights immediately after the intravenous injection of RB at 15 or 30 mg/
kg i.v. (Fig. 1A), though it became visible again 10 min after the irra-
diation. When the local microcirculatory blood perfusion through ca-
pillaries, arterioles, venules and shunting vessels was monitored, it was
found that the blood flow was rapidly decreased to approximately 30%
of baseline at 15 min and maintained throughout 24 h in the case with
30 mg/kg i.v. of RB, though it was partial and unstable in the case with
15 mg/kg i.v. of RB (Fig. 1A). Scars are found sporadically in damaged
cortical and striatal regions showing blanked TTC staining (Fig. 1B). As
shown in Fig. 1C, HE-staining reveals that PIT stress causes the edema
and sporadic clots in the ipsilateral left hemisphere, including sensory
cortex (S-I) and striatum, but not in the ventral postero-lateral/medial
thalamus (VP) at 24 h. The PIT-induced infarct volume was significantly
decreased by tPA infusion, which had been given at 1 or 3 h, but not 4.5
or 6 h (Fig. 1D and E).
3.2. Bilateral hyperalgesia in the EPW test by PIT
EPW test is reported to recognize three types of nociceptive fiber-
related responses. Previous studies demonstrated that C-fiber-mediated
responses are roughly related to 5 Hz stimuli, Aδ responses to 250 Hz
and Aβ ones to 2000 Hz stimuli, respectively (Matsumoto et al., 2008;
Ueda, 2008; Koga et al., 2005). Fig. 2A demonstrates the experimental
schedule of nociception tests with different electrical frequencies. The
PIT stress alone showed significant decreases in the threshold with
2000 or 250 Hz from day 4 or 5 to day 18 or 19, respectively on both
sides of paw (Fig. 2B and C), but did not affect the nociceptive threshold
with 5 Hz stimuli at days 3, 10 and 17 (Fig. 2D). However, the PIT stress
did not show any significant difference in nociceptive threshold in both
thermal and mechanical tests through 3–18 days after the PIT (Fig. 2E
and F). Furthermore, the photo-illumination without RB did not affect
the threshold with 2000 Hz at day 11 (Supplementary Fig. 1).
Supplementary data associated with this article can be found, in the
online version, at https://doi.org/10.1016/j.ynpai.2018.07.001.
3.3. Weak hyperalgesia in thermal and mechanical nociception tests by
4.5 h tPA after PIT
When tPA was given 4.5 h after the PIT stress (Fig. 3A), weak, but
not significant hyperalgesia was observed on both sides at day 17 in the
thermal nociception test (Fig. 3B), while significant hyperalgesia was
observed only on the left side in the mechanical test at day 18 (Fig. 3C).
3.4. Complete blockade of EPW hyperalgesia induced by 6.0 h tPA after PIT
in LPA1 or LPA3-KO mice
As seen in Fig. 4A and B, the PIT-induced decrease in the threshold
in 2000 Hz nociceptive responses on both sides at day 18 were further
enhanced by the administration with tPA given at 6 h after the PIT
stress. The enhancement of hyperalgesia was also observed at day 19
with 250 Hz nociceptive responses (Fig. 4C), while any change was not
observed at day 17 with 5 Hz nociceptive responses (Fig. 4D). Fur-
thermore, the hyperalgesia with PIT alone and PIT + tPA (6 h) with
2000 or 250 Hz was completely abolished in LPA1-KO mice, while the
lack of effect with 5 Hz stimulation remained in LPA1-KO mice. All
these changes were quite similar in the results obtained at day 4 and 11
(Supplementary Fig. 2A–G).
3.5. Potent hyperalgesia in thermal and mechanical nociception tests by
6.0 h tPA and its blockade in LPA1 or LPA3 KO mice
When tPA was treated at 6 h after the PIT, significant hyperalgesia
in thermal and mechanical tests was observed on both sides day 17 and
18, respectively, and these abnormal pain behaviors were completely
abolished in LPA1-KO and LPA3-KO mice (Fig. 5A and B). Similar
Fig. 3. Imperfect occurrence of chronic thermal and
mechanical hyperalgesia by 4.5 h tPA after PIT. (A)
Experimental time schedule. (B, C) Weak thermal (B)
and mechanical (C) hyperalgesia by the treatment
with PIT alone or PIT + tPA. tPA was administered
4.5 h after the PIT treatment. Data show the
means ± S.E.M. *p < 0.05, **p < 0.01, one-way
ANOVA followed by Tukey’s multiple comparisons
test. (F2,22 = 3.64, P = 0.0431).
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abnormal pain and its reversal in LPA1-KO mice were also observed at
earlier time points day 3, 4, 10 and 11 (Supplementary Fig. 3A–E).
3.6. Evidence for the therapeutic potency of LPA1/3 antagonist against the
late tPA-induced post-stroke pain
For the purpose to see the therapeutic effects of LPA receptor an-
tagonist, Ki-16425, which has potent affinity to LPA1 and LPA3 (Ohta
et al., 2003), was administered twice daily from day 11 to day 16
(Fig. 6A). As shown in Fig. 6B and C, the established thermal and me-
chanical hyperalgesia induced by tPA at 6 h after the PIT were both
significantly inhibited by Ki-16425.
3.7. LC–MS/MS analyses of LPA production induced by tPA at 6 h after the
PIT
LC–MS/MS of LPA amounts in the brain loci was performed
(Fig. 7A). For the quantitation of each LPA-species (18:1-, 16:0-, 18:0-
and 20:4-LPA), their signal intensities in LC-MS/MS to that of 17:0-LPA
were used. Aliquots (1/16th of total MtOH extracts) with 0.625 pmol
17:0-LPA were injected to LC. The MS signal ratio of each LPA species
to 17:0-LPA demonstrates that the level of 18:1-LPA was the highest
among 4 LPA species, while that of 20:4-LPA was the lowest in all brain
loci (Fig. 7B). Fig. 7C–E represent the change in the amounts of each
LPA species in different brain loci following the treatments with sham,
PIT or PIT + tPA, when the amounts in the contralateral sham-treated
brain loci (S-I/II, striatum or VP thalamus) or in the combined (ipsi-
lateral + contralateral) MD thalamus was set as 1. In the S-I/II, the PIT
treatment showed some increases in the levels of all 4 LPA-species on
the ipsilateral side, but the significant changes were observed only with
16:0- and 18:0-LPA, but not with 18:1- or 20:4-LPA. The tPA treatment
at 6 h after the PIT showed a little further, but not significant increase in
all 4 LPA-species. Although there were no significant changes in all
LPA-species by PIT or PIT + tPA in the striatum and VP thalamus
(Fig. 7D and E), significant increases in the levels of all 4-species of LPA
in the MD thalamus were observed by PIT + tPA treatment (Fig. 7F).
Throughout the experiments, LC-MS/MS analysis did not detect the
level of 18:2-LPA, which is abundantly observed in the plasma
(Ackerman et al., 2016; Aoki et al., 2008; Kurano et al., 2015).
4. Discussion
The lesion responsible for pain in CPSP was initially claimed that it
is located at the contralateral thalamus, and the syndrome was for years
called ‘thalamic syndrome’ (Dejerine and Roussy, 1906). It is now well
established that lesions causing central pain after stroke can be located
anywhere along the somatosensory projection system, such as in the
lateral medulla, in other parts of the brain stem, in the thalamus, or
beyond the thalamus, including the cortex and the operculum (Boivie
et al., 1989; Klit et al., 2009). For this reason, the term ‘thalamic pain’
has been abandoned and substituted by the broader and more appro-
priate term CPSP, which is a neuropathic pain syndrome that can occur
after a cerebrovascular injury, and might indicate the dual combination
of deafferentation and subsequent development of hyperalgesia due to
neuroplasticity.
In the present study, PIT to occlude the MCA caused a rapid de-
crease in the blood flow in a dose-dependent manner of RB. We adopted
the use of 30 mg/kg i.v. of RB for obtaining more stable decrease in
Fig. 4. Complete blockade of 6 h tPA-enhanced PIT-induced EPW hyperalgesia in LPA1-KO mice. (A) Experimental time schedule. (B–D) EPW hyperalgesia at 2000 Hz
and 250 Hz enhanced by tPA 6 h after the PIT and blockade in WT or LPA1-KO mice. Results represent the threshold (μA) of 2000 Hz (B), 250 Hz (C) and 5 Hz (D) to
cause nociceptive paw withdrawal. Data show the means ± S.E.M. *p < 0.05, **p < 0.01, two-way ANOVA followed by Tukey’s multiple comparisons test. ((B)
Interaction, F6,60 = 8.278, P < 0.0001, Treatment, F3,60 = 32.82, P < 0.0001, Drug, F2,60 = 17.48, P < 0.0001; (C) Interaction, F6,60 = 14.31, P < 0.0001,
Treatment, F3,60 = 41.76, P < 0.0001, Drug, F2,60 = 25.47, P < 0.0001).
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Fig. 5. Complete blockade of 6 h tPA-enhanced PIT-induced thermal and mechanical hyperalgesia in LPA1- and LPA3-KO mice. (A, B) Blockade of hyperalgesia
induced by tPA 6 h after the PIT in LPA1- and LPA3-KO mice. Results represent the PWL of thermal hyperalgesia (A) and PWT of mechanical hyperalgesia (B) to cause
nociceptive paw withdrawal. Data show the means ± S.E.M. *p < 0.05, **p < 0.01, #p < 0.05, ##p < 0.01, two-way ANOVA followed by Bonferroni’s and
Tukey’s multiple comparisons test. ((A) Interaction, F5,54 = 5.807, P = 0.0002, Treatment, F5,54 = 9.066, P < 0.0001, Drug, F1,54 = 8.584, P = 0.005; (B)
Interaction, F5,54 = 8.212, P < 0.0001, Treatment, F5,54 = 9.556, P < 0.0001, Drug, F1,54 = 21.71, P < 0.0001).
Fig. 6. Therapeutic effects of LPA1/3 antagonist on established CPSP. (A) Experimental time schedule. (B, C) Reversal of thermal and mechanical hyperalgesia by
repeated treatments with Ki16425. Ki-16425 at 30 mg/kg (i.p.) was treated twice daily from immediately after the nociception test on Day 11 till Day 16. Data show
the means ± S.E.M. *p < 0.05, **p < 0.01, Unpaired t-test. ((B) Day10 Left, F8,3 = 2.19, P = 0.5601; Day10 Right, F8,3 = 1.327, P = 0.8990; (C) Day11 Left,
F9,3 = 4.142, P = 0.2693; Day11 Right, F3,8 = 1.89, P = 0.4193). #p < 0.05, ##p < 0.01, one-way ANOVA followed by Tukey’s multiple comparisons test. ((B)
Day17 Left, F2,10 = 8.742, P = 0.0064; Day17 Right, F2,10 = 12.27, P = 0.0020; (C) Day18 Left, F2,9 = 21.91, P = 0.0003; Day18 Right, F2,10 = 8.208, P = 0.0078).
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cerebral blood flow. Under this condition, however, the decrease in the
blood flow lasted for more than 24 h, though there was a rapid recovery
of blood flow at MCA, possibly due to the action by endogenous
plasmin. It is interesting to speculate that small blood clots derived
from MCA thrombus are migrated and occlude small vessels in the
distal regions, such as cerebral cortex and striatum. This view may be
supported by the findings that scars are found sporadically in damaged
cortical and striatal regions showing blanked TTC staining. From this
point of view, the present PIT model in mice may be considered as a
Lacunar infarction model. The infarction at 24 h was significantly re-
versed by tPA, which was given at 1 or 3 h after the start of PIT-induced
occlusion, while no significant beneficial effects were observed with
tPA given at 4.5 or 6 h. Taking the fact into account that the tPA-
treatment at 4.5 h for cerebral ischemia is beneficial to the prevention
of motor dysfunction in clinic, the time-period of tPA-administration at
4.5 h seems to be critical in terms of benefit to the prevention of CPSP.
In the previous study, we reported that significant hyperalgesia in
the EPW test were observed by a very short-term transient middle
cerebral artery occlusion (tMCAO) for 15 min, which did not show any
disturbance in the motor dysfunction (Halder et al., 2013b). In the
15 min tMCAO model, however, neither thermal nor mechanical hy-
peralgesia was observed. Similar results were also observed when mice
were given with the present PIT-treatment alone on the left MCA, which
caused hyperalgesia to the stimulation of paw with 250 and 2000 Hz,
being supposed to stimulate Aδ and Aβ fibers, respectively (Matsumoto
et al., 2008; Ueda, 2008), though neither significant thermal nor me-
chanical hyperalgesia was observed. It should be noted that the hy-
peralgesia at 250 and 2000 Hz in the EPW test was observed on both
Fig. 7. LC–MS/MS measurements of LPA species in brain loci of CPSP-model mice. (A) The loci used for the LPA measurements were indicated by circles. (B) Relative
abundancy of 4 species of LPA-molecules in various brain loci. The ratio of MS signal of 18:1-, 16:0-. 18:0 or 20:4-LPA to that of 17:0-LPA per injection was obtained.
Results represent the relative abundancy of each species of LPA-molecules to 18:1-LPA. (C–F) LPA levels in various brain loci on both contra- and ipsilateral sides
following sham, PIT alone and PIT + tPA-treatments. For the abundance of each species of LPA molecules, the ratio of the MS signal of 18:1-, 16:0-. 18:0 or 20:4-LPA
to that of 17:0-LPA per dissected locus as an internal standard was evaluated. Protein levels in each brain locus used for the LPA measurement (n = 6) were
281 ± 23, 431 ± 23, 397 ± 43 and 670 ± 45 μg protein/locus of somatosensory cortex S-I/II, striatum, VP thalamus and MD-thalamus, respectively. Results
represent the relative abundance of each species of LPA molecules in corresponding brain loci when the level at the contralateral side of sham-treated mice was 1.
Data show the means ± S.E.M. *p < 0.05, **p < 0.01, two-way ANOVA followed by Bonferroni’s multiple comparisons test. ((B) 18:1, Interaction, F2,54 = 1.548,
P = 0.222, Treatment, F1,54 = 6.753, P = 0.0120, Drug, F2,54 = 1.746, P = 0.1841; 16:0, Interaction, F2,54 = 1.735, P = 0.1861, treatment, F1,54 = 6.858,
P = 0.0114, Drug, F2,54 = 1.961, P = 0.1506; 18:0, Interaction, F2,54 = 4.014, P = 0.0237, Treatment, F1,54 = 15.98, P = 0.0002, Drug, F2,54 = 7.162, P = 0.0017;
20:4, Interaction, F2,54 = 1.22, P = 0.3032, Treatment, F1,54 = 6.019, P = 0.0174, Drug, F2,54 = 1.362, P = 0.2648). #p < 0.05, ##p < 0.01, one-way ANOVA
followed by Tukey’s multiple comparisons test. ((B) 18:0, F2,30 = 7.606, P = 0.0021; (F) 18:1, F2,22 = 5.599, P = 0.0108; 16:0, F2,22 = 10.16, P = 0.0008; 18:0,
F2,22 = 4.222, P = 0.0281; 20:4, F2,22 = 11.21, P = 0.0004). ††p < 0.05, F test (F10,9 = 708.8, P < 0.0001) and nonparametric Mann-Whitney test.
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sides, despite the left side MCA was occluded by PIT. When tPA was
given at 4.5 h after the PIT, there were some significant thermal and
mechanical hyperalgesia, but the hyperalgesia was not stable. Re-
garding the findings that only A-fiber responses, but not C-fiber ones
showed hyperalgesia, Gritsch et al. (2016) has also reported that CPSP
is not observed with C-fiber responses. As this issue seems to be related
to the differential pain pathways between A-fibers and C-fibers, which
may be differentially affected by the ischemic damages by PIT, the clear
answer should wait for future studies. However, it should be noted that
the peripheral nerve injury causes the hypersensitivity to A-fiber sti-
muli, but hyposensitivity to C-fiber ones (Uchida et al., 2010). There-
fore, it appears that C-fiber nociceptive responses are not always similar
to A-fiber ones.
The long-lasting hyperalgesia at 250 and 2000 Hz in the EPW test
was further strengthen equally on both sides by tPA at 6 h, though there
was still no change in the threshold with 5 Hz stimulation. It should be
noted that long-lasting and significant thermal and mechanical hyper-
algesia were also observed equally on both sides with the treatment of
6 h tPA + PIT. The CPSP-type neuropathic pain was completely abol-
ished in LPA1- and LPA3-KO mice, as seen in the case with partial sciatic
nerve injury-induced neuropathic pain model, though the peripheral
neuropathic pain only shows the hyperalgesia on the ipsilateral side
(Inoue et al., 2004; Ma et al., 2009). As recent studies revealed that
both LPA1 and LPA3 are involved in the self-amplification of LPA pro-
duction through microglia in the spinal cord (Ma et al., 2009, 2013,
2010; Ueda, 2017), similar feed-forward mechanisms of LPA produc-
tion may be also working in the brain after PIT or PIT + tPA treatments.
Of most importance is the finding that the repeated treatments with Ki-
16425, an LPA1 and LPA3 antagonist twice daily for 6 days from day 11
significantly reversed the established thermal or mechanical hyper-
algesia at day 17 or 18, respectively. Therefore, it is evident that LPA1
and LPA3 signal inhibitors, including receptors antagonist and in-
hibitors of enzymes for LPA synthesis would be promising to success-
fully treat the CPSP, as reported in the case of experimental fi-
bromyalgia-like pain models (Ueda and Neyama, 2017).
Bilateral hyperalgesia following the left tMCAO is another im-
portant issue to be discussed. Several studies demonstrated that the
bilateral central pain sensitization in rats occurs following unilateral
thalamic or spinothalamic lesion (Castel et al., 2013; Wang and
Thompson, 2008). Bilateral sensory abnormalities have been described
in a few cases (Kim, 1998). Bilateral processing of pain hypersensitivity
resulting from unilateral injury has been shown to occur in human and
could be explained by the functional changes in somatosensory cortex,
thalamus, insula and anterior cingulate cortex (Coghill et al., 1999;
Davis et al., 1998; Hsieh et al., 1995).
In order to prove the evidence for LPA production at brain areas
underlying bilateral hyperalgesia resulting from unilateral ischemic
injury, we attempted to measure the LPA production in brain loci fol-
lowing PIT + tPA treatments on the analogy of mechanisms underlying
pSNL-induced peripheral neuropathic pain, which is not only abolished
in LPA1- and LPA3-KO mice, but also facilitated by a feed-forward
system of LPA production (Ma et al., 2009, 2013, 2010; Uchida et al.,
2014; Ueda, 2017; Ueda et al., 2018). The levels of 16:0- and 18:0-LPA
were increased in the S-I/II sensory cortex by PIT alone, but there were
no changes by the additional treatment with tPA. It should be noticed
that neither PIT alone nor PIT + tPA affected the LPA levels in the
striatum, which is expected to be damaged by the MCA occlusion and
reperfusion as well as S-I/II sensory cortex. These results indicate that
damage-induced LPA production seems to be locus-specific. Of most
interest is the findings that significant tPA-dependent increase in the
amounts of 4 LPA-species in PIT-treated mice was observed in the MD,
though no significant increase was observed in the VP thalamus. Al-
though the underlying mechanisms remain elusive, it is interesting to
speculate that the tPA-induced elevation of LPA molecules in the MD
may be the secondary event by the physical compression by swelling of
left hemisphere. However, it is unlikely that these changes are
attributed to the leakage of plasma LPA by tPA-induced hemorrhage,
since there was no significant detection of 18:2-LPA, which is abundant
in the plasma (Ackerman et al., 2016; Aoki et al., 2008; Kurano et al.,
2015). Regarding the bilateral hyperalgesia, there are reports that
medial thalamus is associated with pain encoding and affective-moti-
vational aspects of pain (Price, 2000) and cognitive functions, including
attentional modulation of nociceptive processing (Bushnell and
Duncan, 1989), and the nucleus is supposedly related to the emotional
central pain (Tseng et al., 2017). Most recently, we have reported that
the intermittent psychological stress (Empathy) induced fibromyalgia-
like generalized pain behaviors, which were abolished in LPA1-KO mice
(Ueda and Neyama, 2017). However, it is too much speculative that
increased levels of LPA in MD play crucial roles in the emotional or
bilateral abnormal pain. We should determine the LPA levels in other
brain loci, which are involved in the commissural or emotional pain
regulation, such as insula, amygdala, habenula and anterior cingulate
cortex at different or more specifically later time points, since the re-
peated treatments with Ki16425, an LPA1/3 antagonist (Swaney et al.,
2010) showed the therapeutic effect against the bilateral chronic pain.
To further identify the precise loci of LPA production related to the
development and maintenance of CPSP, we are in progress of Imaging
Mass Spectrometry of LPA levels, which may lead to a study of func-
tional proof by antisense treatments.
In conclusion, we successfully developed a mouse model for the
experimental long-lasting CPSP in the thermal and mechanical noci-
ception tests as well as EPW test, which was enabled by the late
treatment with tPA 6 h after the PIT. LC–MS/MS analysis revealed the
tPA-induced LPA production in the MD, but not VP thalamus, which
may explain one of reasons underlying the occurrence of bilateral hy-
peralgesia following the left PIT. As in the case with peripheral neu-
ropathic pain or experimental fibromyalgia models, the PIT + tPA-in-
duced hyperalgesia was abolished in LPA1- and LPA3-KO mice. More
importantly, the established CPSP was also blocked by the repeated i.p.
treatments with LPA1/3 antagonist, Ki-16425.
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